Mirati Therapeutics (NASDAQ:MRTX) Earns Sell Rating from Ana

StockNews.com initiated coverage on shares of Mirati Therapeutics (NASDAQ:MRTX – Free Report) in a report published on Sunday. The brokerage issued a sell rating on the biotechnology company’s stock. A number of other research firms also recently commented on MRTX. SVB Leerink reaffirmed a market perform rating and issued a $58.00 target price (down previously […]

Related Keywords

United States , America , Jamie Christensen , Piper Sandler , Goldman Sachs Group Inc , Securities Exchange Commission , Mirati Therapeutics Inc , Mirati Therapeutics Company Profile , Mirati Therapeutics , Free Report , Get Free Report , Exchange Commission , Sachs Group , Capital Partners , Mirati Therapeutics Daily , Nasdaq Mrtx , Mrtx , Medical , Initiated Coverage , Stocknews Com ,